REspiratory Syncytial virus Consortium in EUrope (RESCEU) study: Defining the burden of disease of Respiratory Syncytial Virus in older adults in Europe. - Burden of disease of RSV in older adults

niversitair Medisch Centrum Utrecht0 个研究点目标入组 356 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

Trial is onging in other countries

•- Current alcohol or drug abuse or history of unsuccessfully treated alcohol or drug abuse within the past year
•- Unable to perform the study procedures
•- Dementia
•- Life expectancy less than 1 year
•- Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination (a more detailed description/list can be found in appendix 3 of the study protocol).
•- Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to study participation. The use of topical, inhaled, and nasal glucocorticoids will be permitted (a more detailed description/list can be found in appendix 3 of the study protocol).
•- Previous participation in this study or in a RSV interventional trial (vaccine, antivirals)
•- Planned leave/holiday during the winter season of more than 1 month in total.

发起方

niversitair Medisch Centrum Utrecht